High quality

Uni-GLP-1 is equivalent to Byetta, and has the advantages of better safety, high activity, low dose, low immunogenicity, less side effects, no risk warning of thyroid C-cell tumor, and good market efficacy verification.

Convenience and good compliance

Uni-GLP-1 adopts needle-free injection technology, which is simple and comfortable to use, easy to carry, and enhances patient confidence. It can not only eliminate needle stick fear and pain, but also improve drug absorption efficiency, reduce drug side effects, and effectively improve patient compliance.

Significant cost advantage

Uni-GLP-1 has the production technology of self-made raw materials, and has stronger cost control ability, and belongs to a state category I New Drug. Therefore, Uni-GLP-1 will be priced more autonomously and flexibly, and the profit margin will be large.

The fastest growing antidiabetic drug

According to public data, the global GLP-1 drug market will reach $16 billion in 2021, and the global GLP-1 drug market is expected to grow to $40.7 billion in 2030. In 2021, the size of China's GLP-1 market will be close to RMB 2.5 billion, an increase of nearly 10 times compared to five years ago.

Weight Loss is in “Blue Ocean”

According to the "Report on Nutrition and Chronic Diseases of Chinese Residents", in 2020, the overweight rate of Chinese adults was 34.3%, and the obesity rate was 16.4%. There are already 600 million overweight and obese people in China, ranking first in the world.

Planning

Uni-GLP-1 liquid formulation is in progress, and will continue to develop weight loss indications and oral innovative dosage forms in the future. During the research, the team found that oral Uni-GLP-1 has a good weight loss effect on DIO mice given long-term administration, and no serious gastrointestinal reactions (vomiting) were found, and the weight loss effect did not show a drastic recovery after the cessation of administration .

The bioavailability of oral Uni-GLP-1 is more than 2 times better than the clinical bioavailability of semaglutide, the marketed oral GLP-1 product found abroad. In the future, Uni-GLP-1 is expected to continue to break through technical barriers and provide patients with medication options with better efficacy and higher compliance.

In addition, the Group is also actively researching and expanding indications, such as NASH, hyperuricemia, Alzheimer's disease, chronic kidney disease and heart failure.